Please ensure Javascript is enabled for purposes of website accessibility AI and the future of healthcare: From innovation to patient impact - Janus Henderson Investors - Mexico Professional Advisor
For professional investors in Mexico

AI and the future of healthcare: From innovation to patient impact

Research Analyst Tim McCarty speaks with Sarah de Lagarde about how artificial intelligence (AI) and technological innovation are reshaping healthcare, offering the potential to improve patient outcomes and creating new investment opportunities across the sector.

17 Nov 2026
7 minute watch

Key takeaways:

  • AI may be an underappreciated tailwind for the healthcare industry. While often associated with drug discovery, AI is increasingly being applied across the healthcare value chain, adding a potential incremental growth driver to a sector that also offers defensive characteristics.
  • Technological advancements are creating opportunities across healthcare subsectors. From robotic surgery and diagnostics to biopharma, AI has the potential to improve patient care, increase efficiency and, over time, enhance research and development (R&D) productivity.
  • We believe deep research is critical to separating innovation from hype. As new technologies emerge, fundamental research can help identify which innovations have the potential to deliver meaningful patient benefits and create attractive long-term investment opportunities.

IMPORTANT INFORMATION

Artificial intelligence (“AI”) focused companies, including those that develop or utilize AI technologies, may face rapid product obsolescence, intense competition, and increased regulatory scrutiny. These companies often rely heavily on intellectual property, invest significantly in research and development, and depend on maintaining and growing consumer demand. Their securities may be more volatile than those of companies offering more established technologies and may be affected by risks tied to the use of AI in business operations, including legal liability or reputational harm.

Equity securities are subject to risks including market risk. Returns will fluctuate in response to issuer, political and economic developments.

Health care industries are subject to government regulation and reimbursement rates, as well as government approval of products and services, which could have a significant effect on price and availability, and can be significantly affected by rapid obsolescence and patent expirations.

Sierra Brown: Sarah, you’re really at the intersection of everything we’re talking about here as far as devices, early detection. I’ve got to know, what is it like to live with technology like this, and maybe even through the lens of ‘is there hype along the way’? What’s real, and what’s hype?

Sarah de Lagarde: That is an excellent question because there is an assumption that when people see me with my robotic limbs that there are some great advantages to this. But the reality is that our bodies are amazing, incredibly complex, incredibly hard to replicate, for sure. So if people ask me, say, well, are there any advantages in having a bionic arm? I would say, well, in day-to-day life, not that much, because my biological left hand is so much more performant than this will ever be. I say this, ever be. maybe not over the five, 10 years. But at the moment, it is still in need of development. However, there’s one thing that this arm can do that is unbeatable, and that is I can modulate the strength of my grip at will.

So I have an app on my phone. Of course I have an app. My children, by the way, find me hilarious. They’re like, oh, mum’s running low on battery. I think we need to plug her into the wall. But there’s always this sense of what is being overhyped and what is reality. And reality is what you can actually do in your day-to-day life with the technology. And some aspects, I realized, engineers are very focused on solving problems that are not necessarily the things that I need in day-to-day life. So that’s the difference there. And where our portfolio management colleagues are extremely good at is that they can see the difference between something that is over-marketed, over-hyped, and something that actually brings real benefit to patients.

What role is AI playing in healthcare innovation?

Tim McCarty: I would characterize AI in healthcare as under the radar and omnipresent. And I think this adds to the investment case of healthcare today. Historically, I’d always call the investment case within healthcare the combination of offense and defense. You have the secular trend of the aging demographics, and then you have the defensive characteristics of a less correlated return stream. that we saw the benefits with last week during the tech sell off. But now I think AI almost turbocharges the secular trend of the offense, and it gives you another secular trend with AI. And a lot of people are familiar with the drug discovery part of the world, and I don’t want to minimize that. But there’s a lot of parts that are under the radar in the healthcare value chain.

How are robotics advancing surgery?

Tim McCarty: Right now It’s acting as a report card for physicians. We’ll get into that in a second. In the future, we think it’s going to democratize healthcare and eliminate medical errors. And then in the long run, we think it’s going to help solve one of the greatest challenges in healthcare today, which is the supply-demand mismatch that exists in healthcare. So let’s take them one at a time.

So the first example right now today is to give doctors a report card on how they’re doing in surgery. So for example, I may be a gallbladder surgeon, Sarah may be best in class, and it will show me, versus a best-in-class doctor, how I’m doing. I may take 20 minutes longer in a procedure. I may use two extra instruments, and it will decompose the surgery and tell you it’s actually step six where you’re deficient and identify training modules on a practice robot to get better. I use the analogy, I played college basketball, and we would watch game film, we would identify deficiency and then do drills to help correct those errors.

In the not-too-distant future, in the short run, I think AI in robotic surgery has the opportunity to eliminate medical errors and democratize surgery. So what do I mean by that? Healthcare is rife with information asymmetry. The bottom-quartile doctors are responsible for a disproportionate amount of medical errors in surgery. Medical errors cost the healthcare system tens of billions of dollars. But the problem is, when a surgeon walks in the room for your exam, no one says, “I’m a bottom quartile doctor,” and just like if I took a poll in this audience and said, “Who’s a below-median driver?” I wouldn’t see many hands go up other than mine. And we think this can really democratize surgery.

And then in the future, we think the real opportunity is almost the Waymo of healthcare. One of the biggest problems facing healthcare systems today is capacity. So right now it’s one surgeon per one person. But in the future, as I talk about, where robots can start doing more of the procedure themselves, you can envision a world where a surgeon is at the top, but they are performing multiple surgeries almost as a pilot simultaneously to help address this capacity bottleneck.

Can AI help combat chronic disease?

Tim McCarty: And the answer is yes. And so we’ll start with cardiovascular disease, which is the number one leading cause of death worldwide. Think 500 million people in the world have cardiovascular disease. I’m going to focus on one specific area of cardiovascular disease called severe aortic stenosis. And this is a valvular heart condition where it’s a narrowing of the aortic valve that, if left untreated, has a 25% mortality rate.

Now, the good news for patients is that there’s a minimally invasive procedure that’s a substitute to open heart surgery performed in 850 centers in the United States. And the opportunity and value proposition for AI here is to improve the diagnosis rate of severe aortic stenosis and thus the treatment rate at every part of the patient journey, from the primary care physician to the general cardiologist to the health system level.

What opportunities does AI offer in drug discovery?

Tim McCarty: I would say the opportunity for AI in drug discovery is to improve research and development (R&D) productivity and eventually lead to greater multiples for biopharmaceutical companies. So what do I mean? Drug discovery is an inherently risky business that is very imperfect. I use what’s called a 10-10 rule. It takes 10 years for a drug to make it to market start to finish. And only 10% of drugs succeed. And it’s really 5% when excluding reformulations.

So AI is now allowing a lot of these companies that are replete with information to interrogate that data and better predict the structure and function and ultimate predictor of success for biologic drugs. This can bend that 10-10 rule and improve R&D productivity. And I think in the future, if we have better R&D productivity, biopharma companies are going to invest more, which is going to lead to more drugs, more candidates, etc.

These are the views of the author at the time of publication and may differ from the views of other individuals/teams at Janus Henderson Investors. References made to individual securities do not constitute a recommendation to buy, sell or hold any security, investment strategy or market sector, and should not be assumed to be profitable. Janus Henderson Investors, its affiliated advisor, or its employees, may have a position in the securities mentioned.

 

Past performance does not predict future returns. The value of an investment and the income from it can fall as well as rise and you may not get back the amount originally invested.

 

The information in this article does not qualify as an investment recommendation.

 

There is no guarantee that past trends will continue, or forecasts will be realised.

 

Marketing Communication.

 

Glossary

 

 

 

Important information

Please read the following important information regarding funds related to this article.

    Specific risks
  • Active management techniques that have worked well in normal market conditions could prove ineffective or negative for performance at other times.
  • Shares can lose value rapidly, and typically involve higher risks than bonds or money market instruments. The value of your investment may fall as a result.
  • Emerging markets expose investors to higher volatility and greater risk of loss than developed markets; they are susceptible to adverse political and economic events, and may be less well regulated with less robust custody and settlement procedures.
  • High exposure to a particular country or geographical region carries a higher level of risk than a more broadly diversified portfolio.
  • Derivatives may be used with the aim of reducing risk or managing the portfolio more efficiently. However, this introduces other risks, in particular, that a derivative counterparty may not meet its contractual obligations.
  • Securities could become hard to value or to sell at a desired time and price, especially in extreme market conditions when asset prices may be falling, increasing the risk of investment losses.
  • Losses could be incurred if a counterparty became unwilling or unable to meet its obligations, or as a result of failure or delay in operational processes or the failure of a third party provider.